AstraZeneca to use ProBioGen’s GlymaxX technology for drug discovery
ProBioGen has agreed a multi-product commercial license with AstraZeneca to use the GlymaxX technology. Following evaluation of the technology under a research license, AstraZeneca will now continue to use GlymaxX and will integrate the technology into their drug discovery. GlymaxX improves target cell killing orchestrated by natural killer cells, thereby enhances antibody-dependent cell-mediated cytotoxicity (ADCC). […]
